Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin

Exclusion Criteria

• •Lactation and/or pregnancy in the previous 6 months before screening, whichever is applicable
• •Intention to become pregnant during the study or within 1 months after the follow up visit
• •History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder
• •Treatment for any major psychiatric disorder in the previous 12 months or use of antidepressant medication before screening
• •Any clinically significant abnormality following review of medical history, laboratory results and physical examination at screening as judged by the Investigator
• •Conditions or disorders that might affect the absorption, distribution, metabolism or excretion of the study drugs
• •Contraindications for the use of oxytocin
• •Hypersensitivity to the active substances or to any of the excipients of the investigational product or reference therapy
• •Present use or use within 30 days before the start of the study medication of one or more of the following medications: antihypertensive drugs, anti-coagulant therapy, medication that could affect myometrial contractility, sex steroids, prostaglandins and its analogues, inhalation anesthetics, vasoconstrictors/sympathomimetics and caudal anesthetics, vasopressin-like drugs
• •Use of any prescribed or over-the-counter medication within 14 days before Day 1
• •Administration of any other investigational drug within 3 months before Day 1 or participation in 3 or more clinical trials in the 10 months before Day 1
• •Loss of more than 500 milliliters (mL) blood during the 3 months before Day 1, or intention to donate blood in the 3 months after completing the study
• •Subjects with a positive test result for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) at screening
• •Subjects with a history of alcohol or drug abuse or with a positive result at screening, for tests of alcohol intake or drugs of abuse